Current concepts in age related macular degeneration
1 October 2008
Volume 09, Issue 4
A review of the modern classifications of AMD and available treatments.
Introduction
Age-related macular degeneration (ARMD) is the commonest cause of visual impairment leading to blind registration among older adults in the western world. Following recently published trials, ophthalmologists around the world now have the knowledge and the drugs to improve visual outcomes and to provide much-needed hope to patients with wet macular degeneration. Further, many research trials are currently under way with more funding to find an even more suitable and effective treatment modality for macular degeneration.
Sign in to view the article
Not a member? Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.
Related further reading
Our Clinical Adviser comments on the story in the BBC about the woman who had gene therapy to try to halt the progression of age-related macular degeneration (AMD).
Our Clinical Adviser offers his advice, following an article by The Express on the best supplements for eyes.
Chris Steele FCOptom, new Clinical Editor of Acuity, on change as a positive factor